ACM
SYRE icon

Aster Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Aster Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$254K Buy
+2,865
New +$209K 0.05% 368
2025
Q2 		– Sell
-126
Closed -$2.48K – 1559
2025
Q1 		$2.48K Buy
+126
New +$2.62K ﹤0.01% 1167

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Aster Capital Management's SYRE Position: Q2 2026 in Review

Aster Capital Management opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 2,865 shares worth $254K. The stake represents 0.05% of the portfolio and ranks #368 among its holdings. This is a return to the name: Aster Capital Management previously reported a position in SYRE as recently as Q1 2025.

Aster Capital Management first reported a position in SYRE in Q1 2025 and has held it in 2 quarters since. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Aster Capital Management held 2,865 shares of Spyre Therapeutics worth $254K as of Q2 2026.
  • Spyre Therapeutics was a new Aster Capital Management position in Q2 2026.
  • Spyre Therapeutics made up 0.05% of Aster Capital Management's portfolio in Q2 2026, its #368 holding.
  • Aster Capital Management first reported a position in Spyre Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.